Connect with us

Health

Patent filed by Pharmacyte Biotech Inc (OTCMKTS:PMCB) To Help Expand Protection Of Cancer Therapy Globally

Published

on

Pharmacyte Biotech Inc (OTCMKTS:PMCB) has moved ahead to make the pronouncement that it has already filed a U.S. patent application and that was with the United States Patent and Trademark Office (USPTO) in a bid to protect its therapy entrusted the facing out of cancerous tumors. In line with this will be a therapy that will be employed in its forthcoming clinical trial in the inoperable, non-metastatic, locally advanced pancreatic cancer (LAPC).

The other thing is that PharmaCyte just succeeded at filing a Patent Cooperation Treaty (PCT) application which will fundamentally be covering the protection of its technology in almost 150 countries spread out beyond the borders of the United States.

Both the PCT and the U.S applications will be most probably be claiming apriority date from a U.S. provisional patent application PharmaCyte which sources indicate could be dated back to March in the previous year.

A person well conversant with the matter but who wanted his identity shielded for reasons best known to him disclosed that the patent applications pulled along with a number of methods of treating several kinds of solid cancerous tumors,-such as those of the colon, breast, liver and pancreas through utilizing the genetically modified human cells which are live and encapsulated.

That is of course done employing the Cell-in-a-Box® technology and the main objective is to do all that it takes to offer lasting solutions to those that have been struggling with cancerous tumors.

PharmaCyte is looking at all the available technologies and takes a strong standpoint that they will be rather beneficial to the significant number of patients who to this point in time haven’t responded to the standard chemotherapies, Abraxane® and gemcitabine being a part of them.

There is great hope at the moment that these new applications might end up being granted and in good time.

But the question is about how they will be beneficial. The point is fundamentally that they will be able deliver the much needed protection for PharmaCyte’s technology over a time span of about 20 years. Much in terms of speculations is moving around regarding what the future brings. But we just have to wait and see.

Advertisement src="//cdn.bannersnack.com/iframe/embed.js">
Advertisement
Advertisement

Title

INDUSTRIAL HEMP3 months ago

Near-Term Headwinds Hit Scotts Miracle-Gro Co (NYSE:SMG) With A Huge Impact

Bank of America Corp (NYSE:BAC) has disclosed that Scotts Miracle-Gro Co (NYSE:SMG) has lately been experiencing several near term risks....

INDUSTRIAL HEMP3 months ago

Argitek Holdings Inc (OTCMKTS:AGTK) To Focus On Acquisition, Revenues & Profitability In 2018

Argitek Holdings Inc (OTCMKTS:AGTK) recently revealed that in 2018, the company’s main focus will be the acquisition, revenues, and profitability....

INDUSTRIAL HEMP3 months ago

PharmaCyte Biotech Inc (OTCMKTS:PMCB) Completes Pore Size Studies & 29 Tests Useful In Pancreatic Cancer Therapy

PharmaCyte Biotech Inc (OTCMKTS:PMCB) has said that the cells it is planning to use in the clinical trial in patients...

INDUSTRIAL HEMP3 months ago

Puration Inc (OTCMKTS:PURA) To Apply For Canadian Recreational Cannabis Cultivation License; To Give EVERx CBD Sports Water Free Samples

Puration Inc (OTCMKTS:PURA) recently announced that it will be applying for the Canadian recreational cannabis cultivation license. The confirmation came...

INDUSTRIAL HEMP3 months ago

Marijuana Company Of America Inc (OTCMKTS:MCOA)’s JV Completes 10,000 Sq. Ft. Greenhouse Set up; Provides Update on Oregon Project

Marijuana Company Of America Inc (OTCMKTS:MCOA) recently announced that its Joint Venture with Bougainville Ventures Inc. based in Washington has...

INDUSTRIAL HEMP3 months ago

Lifestyle Delivery Systems Inc.(OTCMKTS:LDSYF)’s CSPA Group Inc. Receives 15000 Reveur Units & 300 Liters Distillates’ Purchase Orders In Two Different Deals

Lifestyle Delivery Systems Inc. (OTCMKTS:LDSYF) recently made two big announcements related to the receipt of two open purchase orders to...

INDUSTRIAL HEMP3 months ago

Viaderma Inc (OTCMKTS:VDRM) Provides Update On Its Flagship Product Vitastem; Signs $250,000 Agreement With Vage Nigeria Ltd.

Viaderma Inc (OTCMKTS:VDRM), a publicly traded specialty pharmaceutical company recently announced an update on the sales of its flagship product...

INDUSTRIAL HEMP3 months ago

Plandai Biotechnology Inc (OTCMKTS:PLPL) Phytofare Gaining Traction in International Markets

Plandai Biotechnology Inc (OTCMKTS:PLPL) recently issued an update following the successful launch of its Phytofare® supplement. Plandai Biotechnology is a...

INDUSTRIAL HEMP3 months ago

MassRoots Inc (OTCMKTS:MSRT) Issues 2018 Annual Shareholder Letter

MassRoots Inc (OTCMKTS:MSRT) has issued its 2018 Annual Shareholder Letter highlighting on its recent developments as well as its plans...

INDUSTRIAL HEMP3 months ago

Players Network (OTCMKTS:PNTV) Signs Binding Letter Of Intent To Acquire A 56,000-Square-Foot, Fully Operating Greenhouse Complex

Players Network (OTCMKTS:PNTV), a leading integrated and diversified cannabis holding company has announced that it has signed a binding Letter...

Advertisement
Advertisement
Advertisement